openPR Logo
Press release

Growth Dynamics on Hemophilia Drugs Market 2018-2025| Key Players: Grifols SA, CSL Behring, Octapharma AG, Pfizer, Inc.,Bioverativ Inc. & more

06-07-2019 07:30 AM CET | Health & Medicine

Press release from: Fortune Business Insights

Growth Dynamics on Hemophilia Drugs Market 2018-2025| Key

The Global Hemophilia Drugs Market covered the value of US$ 9875.4 Mn in the year 2017 and is anticipated to reach US$ 15830.3 Mn by 2025. Furthermore, the global market for hemodialysis is expected to report a CAGR of 6.0% during the forecast period. The above information was published in a report, titled “Hemophilia Drugs Market Size, Share and Global Trend by Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025.”

The rising prevalence of severe diseases is one of the major concerns in the healthcare industry. Among these disorders, patients with hemophilia suffer from an abnormal blood loss and this weakens their blood clotting process. Companies are introducing novel hemophilia drugs and therapies to fulfill the unmet needs of patients and maintain their quality of life.

Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hemophilia-drugs-market-100068

A lead analyst at Fortune Business Insights said, “Companies are building expansion strategies to develop new hemophilia drugs so as to offer a better diagnosis.” Among disease indications, hemophilia A is projected to exhibit strong growth in the coming years. In addition to this, this segment covered a share of 85% in the global hemophilia drugs market in 2017.

This is mainly attributable to the rising pool patients suffering from hemophilia across the world. Also, rising initiatives at developing and commercializing new products for the effective treatment of hemophilia is driving this segment’s growth. Following hemophilia A, hemophilia B drugs are also expected to grow at a considerable rate in the years to come.

Some of the Main Key Players Covered in the Report

• Grifols SA
• CSL Behring
• Octapharma
• Pfizer
• Bioverativ Inc.
• FERRING LÄKEMEDEL AB
• Aptevo Therapeutics
• Takeda Pharmaceutical Company Limited
• Roche Ltd
• Novo Nordisk

The Asia Pacific to Grow at a Rapid Pace with Rising Number of Hemophilia Patients

North America is projected to emerge dominant in the global hemophilia drugs market during the forecast period. This is mainly ascribable to the rising prevalence of hemophilia A and B, especially in countries such as Canada and the U.S. Moreover, in 2017, North America market for hemophilia drugs covered a value of US$ 3,684.7 Mn. Trailing North America, Europe is the second-leading region in the global hemophilia drugs market.

The growth in this region is attributable to the rising healthcare budgets by governments and initiatives by governments to promote hemophilia drugs treatment. On the other hand, the hemophilia drugs market in the Asia Pacific is likely to expand at a higher CAGR between 2017 and 2025 on account of the rising number of patients suffering from hemophilia especially in countries such as China and India.

Rising Awareness About Hemophilia to Augment the Demand

The primary factor augmenting the hemophilia drugs market is the recent developments in hemophilia treatment. A lead analyst at Fortune Business Insights said: “Several new drugs are expected to enter the global market in the coming years.” Also, hemophilia surgical management is gaining traction on account of increasing awareness about hemophilia across the world.

Moreover, governments are planning to conduct awareness initiatives to spread knowledge regarding the use of hemophilia treatment and drugs This, in turn, is expected to drive the hemophilia drugs market over the next few years. The genetic evolution is leading to rising incidences of bleeding disorders across the world.

This will further lead to hemophilia drug development in the next few years to come. As per the study conducted by the National Hemophilia Foundation or NHF in 2015, about 1% of the U.S. population is likely to suffer from a disease called von Willebrand, hence rising the need for hemophilia treatment drugs.

Pfizer Introduced Gene Therapy to Address Unmet Patient’s Needs

Some of the leading players presently operating in the global market for hemophilia drugs are Grifols SA, Bioverativ Inc., FERRING LÄKEMEDEL AB, Aptevo Therapeutics, Hoffmann-La Roche Ltd, Novo Nordisk, Pfizer, Inc., and CSL Behring. In 2018, companies such as Novo Nordisk, Takeda Pharmaceutical Company Ltd., and F. Hoffmann-La Roche Ltd covered more than half of the share in the global hemodialysis market as per revenue. In 2017, Pfizer, Inc. collaborated with Sangamo Therapeutics, Inc. to commercialize and develop gene therapy programs. The aim was to utilize these programs for Hemophilia A drugs.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/hemophilia-drugs-market-100068

Contact Us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Growth Dynamics on Hemophilia Drugs Market 2018-2025| Key Players: Grifols SA, CSL Behring, Octapharma AG, Pfizer, Inc.,Bioverativ Inc. & more here

News-ID: 1767437 • Views:

More Releases from Fortune Business Insights

Reverse Flame Steam Boiler Market 2023 Dynamics, Major Players, SWOT Analysis, a …
Overview of the Global Reverse Flame Steam Boiler Market 2030: The report discusses everything a marketer requires before investing in the global Reverse Flame Steam Boiler Market during the forecast period 2023-2030. Reverse Flame Steam Boiler Market Size, Share And Global Trend By Capacity (Up to 100kW, 100-1000 kW, Above 1000 kW), By End-Use (Food Industry, Chemical Industry, Refineries, Metal Industry, Power Plant), And Geography Forecast Till 2022-2029. It provides detailed
Syngas and Derivatives Market Research Analysis, Size, Share, Growth Highlights …
Overview of the Global Syngas and Derivatives Market 2030: The report discusses everything a marketer requires before investing in the global Syngas and Derivatives Market during the forecast period 2023-2030. Syngas and Derivatives Market Size, Share and Global Trend By Feedstock(Coal, Petroleum, Natural Gas, Biomass), By Technology(Partial Oxidation, Steam Reforming, Auto-Thermal Reforming, and others), By End User(Chemicals, Power Generation, Liquid Fuels, Gaseous Fuels), and Geography Forecast till 2022-2029. It provides detailed
Port equipment Market Will Experience An Upswing In Demand, Driven By Top Players | Liebherr (Switzerland), TTS Group (Norway), Kalmar (Finland) Konecranes (Finland) |
Port equipment Market Will Experience An Upswing In Demand, Driven By Top Player …
The Port equipment Market Research Report provides an in-depth analysis of the market landscape and identifies future growth opportunities and trends until 2030. By offering valuable insights, the report enables companies to make informed decisions on business strategies and identify potential areas for growth. With a comprehensive assessment of the market, it equips businesses with the necessary tools to stay ahead of the competition. With this Port equipment Market research report,
Modular Chillers Market to reach USD 6.13 billion by 2026, at a CARG of 6.2% | LG Electronics, Mitsubishi Electric Corporation , Haier Group, Midea Group
Modular Chillers Market to reach USD 6.13 billion by 2026, at a CARG of 6.2% | L …
The Modular Chillers Market Report 2023 by Fortune Business Insights provides a comprehensive overview of the market's latest trends, size, regulations, key players, and strategies. The report offers valuable insights into the market's sales and revenue, product type, applications, regions, and leading players. Modular Chillers Market report also covers key players and competitor analysis, providing a comprehensive understanding of the industry's commercial landscape. The report is useful for gaining insights

All 5 Releases


More Releases for Hemophilia

Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes
Hemophilia Treatment Drugs Market Report 2024
Global Hemophilia Treatment Drugs Market: Overview The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia